Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yongzhen Liu has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Liver-specific Mettl14 deletion induces nuclear heterotypia and dysregulates RNA export machinery

    by Keith A Berggren, Saloni Sinha, Aaron E Lin, Michael P Schwoerer, Stephanie Maya, Abhishek Biswas, Thomas R Cafiero, Yongzhen Liu, Hans P Gertje, Saori Suzuki, et al.

    Modification of RNA with N 6 -methyladenosine (m 6 A) has gained attention in recent years as a general mechanism of gene regulation. In the liver, m 6 A, along with its associated machinery, has been studied as a potential biomarker of disease and cancer, with impacts on metabolism, cell cycle regulation, and pro-cancer state signaling. However these observational data have yet to be causally examined in vivo. For example, neither perturbation of the key m 6 A writers Mettl3 and Mettl14 , nor the m 6 A readers Ythdf1 and Ythdf2 have been thoroughly mechanistically characterized in vivo as they have been in vitro . To understand the functions of these machineries, we developed mouse models and found that deleting Mettl14 led to progressive liver injury characterized by nuclear heterotypia, with changes in mRNA splicing, processing and export leading to increases in mRNA surveillance and recycling.

  • Open Access

    Development of a dual channel detection system for pan-genotypic simultaneous quantification of hepatitis B and delta viruses

    by Yongzhen Liu, Stephanie Maya, Sebastian Carver, Aoife K. O’COnnell, Anna E. Tseng, Hans P. Gertje, Kathleen Seneca, Ronald G. Nahass, Nicholas A. Crossland, Alexander Ploss

    Hepatitis B virus (HBV) infection remains a major public health problem as the etiological agent for acute and chronic hepatitis B with about 2 billion people exposed to this virus and at least 257...

  • Open Access

    Targeted viral adaptation generates a simian-tropic hepatitis B virus that infects marmoset cells

    by Yongzhen Liu, Thomas R. Cafiero, Debby Park, Abhishek Biswas, Benjamin Y. Winer, Cheul H. Cho, Yaron Bram, Vasuretha Chandar, Aoife K. O’ Connell, Hans P. Gertje, et al.

    Hepatitis B virus (HBV) only infects humans and chimpanzees, posing major challenges for modeling HBV infection and chronic viral hepatitis. The major barrier in establishing HBV infection in non-human primates lies at incompatibilities between HBV and simian orthologues of the HBV receptor, sodium taurocholate co-transporting polypeptide (NTCP). Through mutagenesis analysis and screening among NTCP orthologues from Old World monkeys, New World monkeys and prosimians, we determined key residues responsible for viral binding and internalization, respectively and identified marmosets as a suitable candidate for HBV infection. Primary marmoset hepatocytes and induced pluripotent stem cell-derived hepatocyte-like cells support HBV and more efficient woolly monkey HBV (WMHBV) infection. Adapted chimeric HBV genome harboring residues 1–48 of WMHBV preS1 generated here led to a more efficient infection than wild-type HBV in primary and stem cell derived marmoset hepatocytes. Collectively, our data demonstrate that minimal targeted simianization of HBV can break the species barrier in small NHPs, paving the path for an HBV primate model.


  • Open Access

    Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses

    by Yongzhen Liu, Debby Park, Thomas R. Cafiero, Yaron Bram, Vasuretha Chandar, Anna Tseng, Hans P. Gertje, Nicholas A. Crossland, Lishan Su, Robert E. Schwartz, et al.


  • Open Access

    Animal Models of Hepatitis B Virus Infection–Success, Challenges, and Future Directions

    by Yongzhen Liu, Stephanie Maya, Alexander Ploss

    Chronic hepatitis B virus (HBV) infection affects more than 250 million people worldwide, which greatly increases the risk for terminal liver diseases, such as liver cirrhosis and hepatocellular carcinoma (HCC). Even though current approved antiviral therapies, including pegylated type I interferon (IFN) and nucleos(t)ide analogs, can effectively suppress viremia, HBV infection is rarely cured. Since HBV exhibits a narrow species tropism and robustly infects only humans and higher primates, progress in HBV research and preclinical testing of antiviral drugs has been hampered by the scarcity of suitable animal models. Fortunately, a series of surrogate animal models have been developed for the study of HBV. An increased understanding of the barriers towards interspecies transmission has aided in the development of human chimeric mice and has greatly paved the way for HBV research in vivo, and for evaluating potential therapies of chronic hepatitis B. In this review, we summarize the currently available animal models for research of HBV and HBV-related hepadnaviruses, and we discuss challenges and future directions for improvement.


  • Open Access

    Analysis on the Development Trend of Marine Fishery Governance

    by Zhi Chen, Chaojie Yang, Wubo Wan, Yongzhen Liu, Zhenbo Chen, Fang Guo

    Marine fishery is an important part of China’s economic development. Marine fishery is not only related to the development of marine economy, but also the marine ecological environment. It is very important to promote the competitiveness of marine fisheries, protect marine ecology, and explore the sustainable development of marine fisheries. In this regard, this article analyzes the development trend of marine fisheries, analyzes the current problems in marine fishery governance, and explores effective countermeasures for the development of marine fishery governance, hoping to provide some ideas for promoting marine fishery governance and enhancing the benefits of marine fishery development.

  • Open Access

    Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination

    by Yongzhen Liu, Hui Liu, Zhanying Hu, Yang Ding, Xiao‐Ben Pan, Jun Zou, Jingyuan Xi, Guangxin Yu, Hongxin Huang, Meng‐Ting Luo, et al.

    Nucleos(t)ide analogues (NAs) have been widely used for the treatment of chronic hepatitis B (CHB). Because viral DNA polymerase lacks proofreading function (3′ exonuclease activity), theoretically, the incorporated NAs would irreversibly terminate viral DNA synthesis. This study explored the natures of nascent hepatitis B virus (HBV) DNA and infectivity of progeny virions produced under NA treatment. HBV infectivity was determined by infection of HepG2‐NTCP cells and primary human hepatocytes (PHHs). Biochemical properties of HBV DNA in the progeny virions were investigated by qPCR, northern blotting, or Southern blotting hybridization, sucrose gradient centrifugation, and in vitro endogenous DNA polymerase assay. Progeny HBV virions produced under NA treatment were mainly not infectious to HepG2‐NTCP cells or PHHs. Biochemical analysis revealed that under NA treatment, HBV DNA in nucleaocapsids or virions were predominantly short minus‐strand DNA with irreversible termination. This finding was supported by the observation of first disappearance of relaxed circular DNA and then the proportional decline of HBV‐DNA levels corresponding to the regions of PreC/C, S, and X genes in serial sera of patients receiving NA treatment. Conclusion: HBV virions produced under NA treatment are predominantly replication deficient because the viral genomes are truncated and elongation of DNA chains is irreversibly terminated. Clinically, our results suggest that the viral loads of CHB patients under NA therapy vary with the different regions of genome being detected by qPCR assays. Our findings also imply that NA prevention of perinatal and sexual HBV transmission as well as infection of transplanted livers works not only by reducing viral loads, but also by producing noninfectious virions.


  • Open Access

    CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice

    by Yongzhen Liu, Xuewei Qi, Zhenzhen Zeng, Lu Wang, Jie Wang, Ting Zhang, Qiang Xu, Congle Shen, Guangde Zhou, Shaomin Yang, et al.

    The p53 mutation and altered Pten expression are two most common genetic events in Hepatitis B virus (HBV) infection related hepatocellular carcinoma (HCC). To confirm the causative role of p53 and Pten somatic mutation in HCC development, we established CRISPR/Cas9-mediated somatic gene disruption via hydrodynamic tail vein injection, allowing for in vivo targeting p53 and Pten simultaneously in adult HBV transgenic mice. Here we demonstrated that the utility of this approach resulted in macroscopic liver tumors as early as 4 months’ post injection and most tumors harbored both p53 and Pten loss-of-function alterations. Immunohistochemical (IHC) and histopathology analysis demonstrated that the tumors were positive for Glutamine synthetase (GS), a marker of HCC and accompanied with prominent lipid accumulation. The study here indicated that CRISPR/Cas9-mediated p53 and Pten somatic mutation accelerated hepatocarcinogenesis in adult HBV transgenic mice. This method also provides a fast and convenient system for generating mouse model of HCC with HBV infection characteristics.